Anebulo Pharmaceuticals, Inc. Anebulo Pharmaceuticals, Inc.Anebulo Pharmaceuticals, Inc. Anebulo Pharmaceuticals, Inc.
  • About Us
  • Pipeline
  • Therapeutic focus
  • Contact us
  • Investors
Open

Press Releases

Investors

Investors

  • Overview
  • News & Events
    • Overview
    • Press Releases
    • IR Calendar
    • Videos
    • Email Alerts
  • Company Info
    • Overview
    • Management Team
    • Presentations
    • Contacts
    • FAQ
  • Financial Info
    • Overview
    • Financial Results
    • Income Statement
    • Balance Sheet
    • Cash Flow
  • Stock Data
    • Quote
    • Charts
    • Historical Data
    • Analyst Coverage
  • SEC Filings
    • Overview
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • Governance
    • Overview
    • Board of Directors
    • Board Committees
    • Governance Documents
    • Board Diversity Matrix
  • News & Events

  • Overview
  • Press Releases
  • IR Calendar
  • Videos
  • Email Alerts
Feb 14, 2025 4:05pm EST

Anebulo Pharmaceuticals Reports Second Quarter Fiscal Year 2025 Financial Results and Recent Updates

Dec 23, 2024 9:15am EST

Anebulo Pharmaceuticals Announces Positive Regulatory Update for Selonabant in Acute Cannabis-Induced Toxicity in Children and Capital Raise

Nov 13, 2024 4:05pm EST

Anebulo Pharmaceuticals Reports First Quarter Fiscal Year 2025 Financial Results and Recent Updates

Sep 25, 2024 4:05pm EDT

Anebulo Pharmaceuticals Reports Fourth Quarter and Fiscal Year 2024 Financial Results and Recent Updates

Jul 22, 2024 7:00am EDT

Anebulo Pharmaceuticals Awarded NIDA Grant for its Investigational IV Treatment for Acute Cannabis-Induced Toxic Effects

May 15, 2024 1:05pm EDT

Anebulo Pharmaceuticals Reports Third Quarter Fiscal Year 2024 Financial Results and Recent Updates

Feb 13, 2024 4:05pm EST

Anebulo Pharmaceuticals Reports Second Quarter Fiscal Year 2024 Financial Results and Recent Updates

Nov 14, 2023 4:05pm EST

Anebulo Pharmaceuticals Reports First Quarter Fiscal Year 2024 Financial Results and Recent Updates

Oct 06, 2023 4:06pm EDT

Anebulo Pharmaceuticals Announces New CEO

Oct 06, 2023 4:06pm EDT

Anebulo Pharmaceuticals Announces Appointment of Bimal Shah to its Board of Directors

  • 1
  • 2
  • 3
  • 4
  • 5
  • arrow_forward
rss_feed News RSS
  • Email Alerts
  • Contacts
  • RSS News Feed

Contact

Anebulo Pharmaceuticals
1017 Ranch Road 620 South
Suite 107
Lakeway, TX 78734
Phone: 512-598-0931
Email: info@anebulo.com

About

Our Mission
Management Team
Board of Directors

Pipeline

  • ANEB-001
Anebulo Pharmaceuticals, Inc.
Facebook Twitter Instagram Reddit
Back to top

©2025 Anebulo Pharmaceuticals. All Rights Reserved.

Privacy Policy | Terms of Use